STOCK TITAN

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.

A live webcast will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay will remain available on Eliem’s website for at least 30 days after the conference.

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

https://eliemtx.com/

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Marites Coulter
Verge Scientific
Mcoulter@vergescientific.com
415.819.2214


Eliem Therapeutics, Inc.

NASDAQ:ELYM

ELYM Rankings

ELYM Latest News

ELYM Stock Data

221.51M
4.52M
26.12%
67.24%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WILMINGTON

About ELYM

eliem therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. headquartered in seattle with r&d primarily in cambridge, uk, eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. these conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. at its core, the eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. eliem is a publicly traded company (nasdaq: elym) read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/